On June 1, 2018, NeoGenomics, Inc., a Nevada corporation (the “Company”), held an annual meeting of its stockholders.At the annual meeting, 76,115,215 shares of the Company’s common stock, par value $0.001 per share, and all 6,864,000 shares of the Company’s Series A redeemable convertible preferred stock, par value $0.001 per share (together with the common stock, “Voting Stock”), were present or represented by proxy at the meeting, representing approximately 95%of the outstanding Voting Stock as of April 2, 2018, the record date for the annual meeting. At the annual meeting, three proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:

(1)Proposal No.1: The election of Douglas M. VanOort, Steven C. Jones, Kevin C. Johnson, Raymond R. Hipp, Bruce K. Crowther, Lynn A. Tetrault, Alison L. Hannah and Stephen M. Kanovsky to serve as members of the Board of Directors until the next succeeding annual meeting of stockholders or until his or her successor has been duly elected and qualified.The stockholders elected the eight directors by the following votes:

(2) Proposal No.2: The approval of the amendment of the amended and restated employee stock purchase plan, as identified in the proxy statement for the annual meeting.The stockholders approved the proposal by the following vote:

(3) Proposal No.3: The ratification of the appointment of the independent registered public accountant.The stockholders approved the proposal by the following vote:

Item 5.07.Financial Statements and Exhibits.

(a) Not applicable

(b) Not applicable

(c) Not applicable

(d)Not applicable

About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.